- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04136327
A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection
A Phase 1, Open-label, Single-center Study to Investigate the Pharmacokinetics and Metabolism of GLPG1972 in Healthy Male Subjects Following Single Intravenous [14C]-GLPG1972 Microtracer and Single Oral [14C]-GLPG1972 Administration
The sponsor wants to investigate in this study how well the test medicine is taken up by the body when given orally (by mouth) as a tablet and solution, and as a solution for infusion (into a vein). The oral solution and solution for infusion will be radiolabelled. 'Radiolabelled' means that the test medicine has a radioactive component which helps us to track where the test medicine is in the body, what it is broken down into, and how it leaves the body.
The sponsor will also look at the safety and tolerability of the test medicine.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Nottingham, Reino Unido, NG11 6JS
- Quotient Sciences Limited
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male between 30-64 years of age (extremes included), on the date of signing the Informed Consent Form (ICF).
- A body mass index (BMI) between 18.0-32.0 kg/m2, inclusive.
- Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and fasting clinical laboratory safety tests. Clinical laboratory safety test results must be within the reference ranges or considered not clinically significant in the opinion of the investigator.
- Having a regular daily defecation pattern (i.e. 1 to 3 times per day).
Exclusion Criteria:
- Known hypersensitivity to IMP ingredients or history of a significant allergic reaction to IMP ingredients as determined by the investigator, and/or known sensitivity to IMP or the excipients (e.g. lactose). Hayfever is allowed unless active.
- History of or a current immunosuppressive condition (e.g. human immunodeficiency virus [HIV] infection).
- Having any illness, judged by the investigator as clinically significant, in the 3 months prior to first investigational medicinal product (IMP) administration.
- Participation in a study with 14C-radiolabeled drug in the last 12 months prior to first IMP administration.
- Radiation exposure, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 millisievert (mSv) in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, can participate in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: GLPG1972 oral and [14C]-GLPG1972 IV
GLPG1972 film-coated tablet followed by [14C]-GLPG1972 solution for infusion
|
single oral dose of GLPG1972
a 15-minute IV infusion [14C]-GLPG1972
|
Experimental: [14C]-GLPG1972 oral solution
|
single oral dose of [14C]-GLPG1972
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change of total radioactivity excreted in urine and feces combined (Period 2)
Prazo: From Day 1 pre-dose up to Day 10
|
To assess the mass balance, using [14C]-GLPG1972
|
From Day 1 pre-dose up to Day 10
|
Maximum observed plasma concentration (Cmax) of total radioactivity (Period 2)
Prazo: From Day 1 pre-dose up to Day 10
|
To assess the pharmacokinetics (PK) of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 10
|
Cmax of GLPG1972 (Period 2)
Prazo: From Day 1 pre-dose up to Day 10
|
To assess the PK of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 10
|
Area under the plasma concentration-time curve (AUC) of total radioactivity (Period 2)
Prazo: From Day 1 pre-dose up to Day 10
|
To assess the PK of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 10
|
AUC of GLPG1972 (Period 2)
Prazo: From Day 1 pre-dose up to Day 10
|
To assess the PK of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 10
|
Change in amount of [14C]-GLPG1972 excreted in urine and feces combined (μg) from baseline at Day 7 (Part 2)
Prazo: From Day 1 pre-dose up to Day 7
|
To characterize the elimination pathways and metabolite profile of GLPG1972
|
From Day 1 pre-dose up to Day 7
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Intravenous (IV) Cmax of [14C]-GLPG1972 microtracer (MT)(Period 1)
Prazo: From Day 1 pre-dose up to Day 4
|
To assess the PK of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 4
|
IV Cmax of total radioactivity (Period 1)
Prazo: From Day 1 pre-dose up to Day 4
|
To assess the PK of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 4
|
IV AUC of [14C]-GLPG1972 MT (Period 1)
Prazo: From Day 1 pre-dose up to Day 4
|
To assess the PK of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 4
|
IV AUC of total radioactivity (Period 1)
Prazo: From Day 1 pre-dose up to Day 4
|
To assess the PK of GLPG1972 and its main metabolites in plasma
|
From Day 1 pre-dose up to Day 4
|
The number of incidents of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs) and TEAEs leading to discontinuations (Period 1 and Period 2)
Prazo: From Day 1 through study completion, an average of 2 months
|
To evaluate the safety and tolerability of GLPG1972 (Period 1 and Period 2)
|
From Day 1 through study completion, an average of 2 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Angela de Haas-Amatsaleh, MD, Galapagos NV
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- GLPG1972-CL-108
- 2019-001305-25 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em GLPG1972 film-coated tablets
-
Health Institutes of TurkeyConcluído